- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01394055
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
September 21, 2016 updated by: Motus Therapeutics, Inc.
Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Able to provide written informed consent prior to any study procedures.
- Diagnosis of Type 1 or 2 diabetic gastroparesis.
- Controlled Type 1 or 2 diabetes mellitus (HbA1c <10.1%).
- Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to Period 1 (daily adjustments of insulin doses are permitted).
- Body mass index of 18-40 kg/m².
Key Exclusion Criteria:
- Unable or unwilling to provide informed consent or to comply with study procedures.
- History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure. (Note: history of diagnostic endoscopy is not exclusionary).
- Acute or chronic illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, poor renal or hepatic function, etc.
- Any clinically significant abnormalities on screening laboratories as determined by the Investigator.
- Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities or blood pressure at screening except minor deviations deemed to be of no clinical significance by the Investigator.
- Poor venous access or inability to tolerate venipuncture.
- Acute GI illness within 48 hours of Period 1.
- Positive pregnancy test.
- Participation in a clinical study within the 30 days prior to dosing in the present study.
- Any other reason, which in the opinion of the Investigator, would confound proper interpretation of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Matching placebo volume subcutaneously once
|
Active Comparator: RM-131
|
100 μg subcutaneously once
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic (PD) effects of RM-131 on gastric emptying
Time Frame: Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2
|
Change from baseline in gastric half-emptying time by scintigraphy (solids and liquids)
|
Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of RM-131
Time Frame: Day 1 and 2 after dosing in Period 1 and Day 1 and 2 after dosing in Period 2
|
Number of participants with adverse events
|
Day 1 and 2 after dosing in Period 1 and Day 1 and 2 after dosing in Period 2
|
Pharmacokinetics (PK) of RM-131
Time Frame: Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2
|
Median T-max of RM-131 levels in patients with type 2 diabetes mellitus
|
Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1453-1459.e4. doi: 10.1016/j.cgh.2013.04.019. Epub 2013 Apr 30.
- Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013 Jan;36(1):41-8. doi: 10.2337/dc12-1128. Epub 2012 Sep 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
July 8, 2011
First Submitted That Met QC Criteria
July 12, 2011
First Posted (Estimate)
July 14, 2011
Study Record Updates
Last Update Posted (Estimate)
September 22, 2016
Last Update Submitted That Met QC Criteria
September 21, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Paralysis
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Gastroparesis
- Diabetes Complications
Other Study ID Numbers
- RM-131-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroparesis
-
Johns Hopkins UniversityCompletedDiabetic Gastroparesis | Idiopathic Gastroparesis | Gastroparesis PostoperativeUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Vanda PharmaceuticalsRecruitingGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Neurogastrx, Inc.CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Texas Tech University Health Sciences Center, El...CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
TakedaCompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsActive, not recruitingGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Millennium Pharmaceuticals, Inc.CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States, Belgium, Japan, Poland
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling by invitationFunctional Dyspepsia | Diabetics Without Symptoms of Gastroparesis | Diabetic Gastroparesis | Idiopathic Gastroparesis | Total or Partial Gastrectomy | Chronic NauseaUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruiting
Clinical Trials on RM-131
-
Motus Therapeutics, Inc.CompletedConstipationUnited States
-
Motus Therapeutics, Inc.CompletedDiabetes Mellitus | Gastroparesis | Diabetes Mellitus ComplicationsUnited States
-
Motus Therapeutics, Inc.CompletedAnorexia NervosaUnited States
-
Motus Therapeutics, Inc.Mayo ClinicCompletedGastric MotilityUnited States
-
AllerganCompletedDiabetes Mellitus | Gastroparesis | Diabetes Mellitus ComplicationsUnited States, United Kingdom, Belgium, Israel, Germany, Poland, Sweden
-
Motus Therapeutics, Inc.Michael J. Fox Foundation for Parkinson's ResearchTerminatedParkinson's DiseaseUnited States
-
Motus Therapeutics, Inc.Mayo ClinicCompletedChronic ConstipationUnited States
-
Assiut UniversityCompletedIntraoperative ComplicationsEgypt
-
Purdue UniversityCompletedCardiovascular Risk Factor | Healthy DietUnited States
-
Rhythm Pharmaceuticals, Inc.Recruiting